Past, present and future of hirudin
Basic science / preclinical published in Haemostasis (1991)
Abstract
The naturally occurring anticoagulant from medicinal leeches, hirudin, which we isolated and biochemically analyzed 30 years ago as a miniprotein with specific antithrombin activity, has afterwards been employed for scientific and diagnostic purposes in hematology. Pure hirudin proved to be an antithrombotic agent of high quality that displays an antithrombotic action dependent upon its blood level. After intravenous injection, it is distributed in the extracellular space and is almost completely eliminated through the kidneys by glomerular filtration in a biologically active form. The efficacy of hirudin in preventing venous and arterial thrombosis and disseminated intravascular coagulation was demonstrated in various animal models. Clinical pharmacological studies corroborated the specific pharmacodynamic and pharmacokinetic properties of hirudin found in animal experiments. Genetic engineering led to the availability of sufficient quantities of recombinant hirudin (r-hirudin) for clinical purposes. Pharmacologic profiling of r-hirudin showed that both its pharmacokinetic and pharmacodynamic characteristics are very similar to those of native hirudin. Clinical pharmacological studies with r-hirudin revealed that, at single therapeutically relevant doses, r-hirudin is a well-tolerated and potent anticoagulant without any detectable side effects and allergic reactions. Further preclinical studies of r-hirudin should concentrate on identifying possible indications for use, on the development of r-hirudin preparations and derivatives, and on the development of antidotes for hirudin.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Summary
The naturally occurring anticoagulant from medicinal leeches, hirudin, which we isolated and biochemically analyzed 30 years ago as a miniprotein with specific antithrombin activity, has afterwards been employed for scientific and diagnostic purposes in hematology.
Why This Matters for Hirudotherapy
This article traces the scientific development of hirudin — the naturally occurring anticoagulant isolated from medicinal leeches — from its biochemical characterization as a specific antithrombin miniprotein through to the production and pharmacological evaluation of recombinant hirudin (r-hirudin). The abstract reports that hirudin's antithrombotic action is dependent upon its blood level, that it distributes in the extracellular space and is eliminated through the kidneys, and that efficacy in preventing venous and arterial thrombosis and disseminated intravascular coagulation was demonstrated in animal models; r-hirudin is described as having pharmacokinetic and pharmacodynamic properties similar to native hirudin and as a well-tolerated, potent anticoagulant at single therapeutically relevant doses in clinical pharmacological studies. This work is central to ASH's domain because hirudin is the principal anticoagulant derived from medicinal leeches, and its pharmacological characterization directly informs leech-based therapy and leech-derived drug development. The abstract provides a broad, multi-decade account rather than detailed quantitative results from any single study, and no large-scale clinical outcome data are presented.
Citation
Added to ASH library: March 18, 2026 · Site last updated: June 18, 2026